SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-004797
Filing Date
2020-04-30
Accepted
2020-04-30 16:16:27
Documents
60
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20200331x10q.htm 10-Q 1741537
2 EX-31.1 crvs-20200331ex3113c4f1a.htm EX-31.1 13515
3 EX-31.2 crvs-20200331ex312567477.htm EX-31.2 13463
4 EX-32.1 crvs-20200331ex3214e2372.htm EX-32.1 13621
5 GRAPHIC crvs20200331x10q001.jpg GRAPHIC 98442
  Complete submission text file 0001558370-20-004797.txt   5632722

Data Files

Seq Description Document Type Size
6 EX-101.INS crvs-20200331.xml EX-101.INS 1085735
7 EX-101.SCH crvs-20200331.xsd EX-101.SCH 35973
8 EX-101.CAL crvs-20200331_cal.xml EX-101.CAL 48430
9 EX-101.DEF crvs-20200331_def.xml EX-101.DEF 109256
10 EX-101.LAB crvs-20200331_lab.xml EX-101.LAB 353955
11 EX-101.PRE crvs-20200331_pre.xml EX-101.PRE 246045
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 20835855
SIC: 2834 Pharmaceutical Preparations